Alpine Immune Sciences, Inc. (ALPN): Price and Financial Metrics

Alpine Immune Sciences, Inc. (ALPN): $7.72

0.22 (+2.93%)

POWR Rating

Component Grades













Add ALPN to Watchlist
Sign Up

Industry: Biotech



in industry


  • Quality is the dimension where ALPN ranks best; there it ranks ahead of 76.3% of US stocks.
  • The strongest trend for ALPN is in Momentum, which has been heading up over the past 177 days.
  • ALPN's current lowest rank is in the Growth metric (where it is better than 9% of US stocks).

ALPN Stock Summary

  • Of note is the ratio of ALPINE IMMUNE SCIENCES INC's sales and general administrative expense to its total operating expenses; just 8.47% of US stocks have a lower such ratio.
  • With a price/sales ratio of 11.83, ALPINE IMMUNE SCIENCES INC has a higher such ratio than 91.44% of stocks in our set.
  • With a year-over-year growth in debt of -27.55%, ALPINE IMMUNE SCIENCES INC's debt growth rate surpasses merely 10.72% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to ALPINE IMMUNE SCIENCES INC, a group of peers worth examining would be SGMO, IDYA, GRTS, PSTX, and TNGX.
  • Visit ALPN's SEC page to see the company's official filings. To visit the company's web site, go to

ALPN Valuation Summary

  • In comparison to the median Healthcare stock, ALPN's price/sales ratio is 521.05% higher, now standing at 11.8.
  • ALPN's price/sales ratio has moved NA NA over the prior 95 months.

Below are key valuation metrics over time for ALPN.

Stock Date P/S P/B P/E EV/EBIT
ALPN 2023-03-24 11.8 2.0 -6.2 -6.5
ALPN 2023-03-23 12.9 2.2 -6.7 -7.1
ALPN 2023-03-22 11.4 2.0 -6.7 -4.8
ALPN 2023-03-21 11.6 2.0 -6.8 -4.9
ALPN 2023-03-20 11.8 2.1 -6.9 -5.1
ALPN 2023-03-17 12.4 2.2 -7.3 -5.4

ALPN Growth Metrics

    The year over year net income to common stockholders growth rate now stands at -42.87%.
  • Its 2 year price growth rate is now at 120%.
  • Its 5 year net income to common stockholders growth rate is now at -7.57%.
Over the past 33 months, ALPN's revenue has gone up $30,078,000.

The table below shows ALPN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 31.818 -41.697 -54.065
2022-06-30 31.967 4.785 -54.286
2022-03-31 33.868 6.172 -47.217
2021-12-31 23.443 -15.248 -50.333
2021-09-30 24.556 -9.868 -41.508
2021-06-30 17.953 -45.394 -34.151

ALPN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALPN has a Quality Grade of C, ranking ahead of 68.11% of graded US stocks.
  • ALPN's asset turnover comes in at 0.122 -- ranking 247th of 682 Pharmaceutical Products stocks.
  • SELB, TXMD, and QGEN are the stocks whose asset turnover ratios are most correlated with ALPN.

The table below shows ALPN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.122 1 -0.458
2021-03-31 0.086 1 -0.661
2020-12-31 0.083 1 -0.777
2020-09-30 0.051 1 -1.140
2020-06-30 0.044 1 -0.895
2020-03-31 0.047 1 -0.716

ALPN Price Target

For more insight on analysts targets of ALPN, see our ALPN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1.25 (Strong Buy)

ALPN Stock Price Chart Interactive Chart >

Price chart for ALPN

ALPN Price/Volume Stats

Current price $7.72 52-week high $9.95
Prev. close $7.49 52-week low $4.82
Day low $7.36 Volume 126,600
Day high $7.82 Avg. volume 90,069
50-day MA $7.95 Dividend yield N/A
200-day MA $7.59 Market Cap 234.70M

Alpine Immune Sciences, Inc. (ALPN) Company Bio

Alpine Immune Sciences, Inc. is focused on developing novel protein‐based immunotherapies using its proprietary Variant Ig Domain vIgD platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which can potentially produce proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to both oncology and inflammatory diseases. The company formed following a July, 2017 merger with Nivalis Therapeutics.

ALPN Latest News Stream

Event/Time News Detail
Loading, please wait...

ALPN Latest Social Stream

Loading social stream, please wait...

View Full ALPN Social Stream

Latest ALPN News From Around the Web

Below are the latest news stories about ALPINE IMMUNE SCIENCES INC that investors may wish to consider to help them evaluate ALPN as an investment opportunity.

Even though Alpine Immune Sciences (NASDAQ:ALPN) has lost US$39m market cap in last 7 days, shareholders are still up 200% over 3 years

Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shareholders might be concerned after seeing the share price drop 13% in...

Yahoo | March 27, 2023

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2022 Earnings Call Transcript

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2022 Earnings Call Transcript March 23, 2023 Operator: Welcome to the Alpine Immune Sciences Fourth Quarter 2022 Earnings Call. Currently, all participants are in listen-only mode. As a reminder, this event is being recorded. I would now like to introduce Temre Johnson, Senior Director of Investor Relations and Corporate […]

Yahoo | March 27, 2023

Q4 2022 Alpine Immune Sciences Inc Earnings Call

Q4 2022 Alpine Immune Sciences Inc Earnings Call

Yahoo | March 24, 2023

Alpine Immune Sciences GAAP EPS of -$0.41 misses by $0.14, revenue of $2.78M misses by $8.18M

  • Alpine Immune Sciences press release (NASDAQ:ALPN): Q4 GAAP EPS of -$0.41 misses by $0.14.
  • Revenue of $2.78M (-38.6% Y/Y) misses by $8.18M.

Seeking Alpha | March 23, 2023

Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -51.85% and 73.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 23, 2023

Read More 'ALPN' Stories Here

ALPN Price Returns

1-mo -3.38%
3-mo 5.03%
6-mo 7.22%
1-year -13.94%
3-year 168.06%
5-year -3.50%
YTD 5.03%
2022 -46.93%
2021 9.92%
2020 228.13%
2019 4.35%
2018 -67.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7461 seconds.